GlassScriptPhysician profile
Alex P Taylor
NPI 1881654192
$10,316.01
in general payments reported to CMS, 2019-2025
18 companies · $6,668 in 2025
The $6,668 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $190 · 2021: $287 · 2022: $724 · 2023: $1,106 · 2024: $736 · 2025: $6,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,250 · Food and Beverage: $3,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,250.00 |
| Food and Beverage | $3,259.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,955.60 | 2020-2025 | Biktarvy, Yeztugo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $988.81 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $677.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $642.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Viiv Healthcare Company | $560.13 | 2020-2025 | Dovato, Apretude |
| Otsuka America Pharmaceutical, INC. | $299.75 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $217.12 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Amgen INC. | $217.08 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $159.82 | 2019-2021 | |
| Janssen Biotech, INC. | $147.82 | 2022-2023 | Symtuza |
| Novartis Pharmaceuticals Corporation | $141.73 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $139.53 | 2019-2024 | Pifeltro, Delstrigo |
| Theratechnologies INC. | $72.31 | 2023 | Egrifta, Trogarzo |
| Glaxosmithkline, LLC. | $30.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.94 | 2023 | Xarelto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $17.06 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $16.25 | 2025 | Zoryve |
| Allergan, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.